204 related articles for article (PubMed ID: 29925907)
21. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.
Schütz C; Inselmann S; Saussele S; Dietz CT; Mu Ller MC; Eigendorff E; Brendel CA; Metzelder SK; Bru Mmendorf TH; Waller C; Dengler J; Goebeler ME; Herbst R; Freunek G; Hanzel S; Illmer T; Wang Y; Lange T; Finkernagel F; Hehlmann R; Huber M; Neubauer A; Hochhaus A; Guilhot J; Xavier Mahon F; Pfirrmann M; Burchert A
Leukemia; 2017 Apr; 31(4):829-836. PubMed ID: 28074067
[TBL] [Abstract][Full Text] [Related]
22. Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value.
Hidalgo-Lόpez JE; Kanagal-Shamanna R; Quesada AE; Gong Z; Wang W; Hu S; Medeiros LJ; Bassett RL; d'Orcy E; Yin CC; Cortes J; Jabbour EJ; Kantarjian HM; Bueso-Ramos CE
Cancer; 2018 Oct; 124(19):3849-3855. PubMed ID: 30321462
[TBL] [Abstract][Full Text] [Related]
23. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
24. The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
Wang J; Hu J; Jin Z; Wan H
Leuk Res; 2016 Aug; 47():32-40. PubMed ID: 27244255
[TBL] [Abstract][Full Text] [Related]
25. Restricted TRBV repertoire in CD4+ and CD8+ T-cell subsets from CML patients.
Li Y; Geng S; Du X; Chen S; Yang L; Wu X; Li B; Schmidt CA; Przybylski GK
Hematology; 2011 Jan; 16(1):43-9. PubMed ID: 21269567
[TBL] [Abstract][Full Text] [Related]
26. The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in "lymphoid" blasts and A comparison of morphologic, immunophenotypic, and molecular findings.
Khalidi HS; Brynes RK; Medeiros LJ; Chang KL; Slovak ML; Snyder DS; Arber DA
Mod Pathol; 1998 Dec; 11(12):1211-21. PubMed ID: 9872654
[TBL] [Abstract][Full Text] [Related]
27. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
28. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
Stock W; Yu D; Karrison T; Sher D; Stone RM; Larson RA; Bloomfield CD
Int J Oncol; 2006 May; 28(5):1099-103. PubMed ID: 16596225
[TBL] [Abstract][Full Text] [Related]
29. Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses.
Kontaki E; Boumpas DT; Tzardi M; Mouzas IA; Papadakis KA; Verginis P
Autoimmunity; 2017 May; 50(3):170-181. PubMed ID: 28276713
[TBL] [Abstract][Full Text] [Related]
30. Colony growth in cultures from bone marrow and peripheral blood after curative treatment for leukemia and severe aplastic anemia.
Betticher DC; Huxol H; Müller R; Speck B; Nissen C
Exp Hematol; 1993 Nov; 21(12):1517-21. PubMed ID: 8405233
[TBL] [Abstract][Full Text] [Related]
31. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
[TBL] [Abstract][Full Text] [Related]
32. [Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek].
Turkina AG; Kruglov SS; Druzhkova GA; Domracheva EV; Zakharova AV; Vinogradova OIu; Sysoeva EP; Diachenko LV; Chelysheva EIu; Zakharova ES; Abakumov EM; Kolosheĭnova TI; Kolosova LIu; Ivanova TV; Zhuravlev VS; Nemchenko IS; Zingerman BV; Kurova ES; Triputen' NZ; Loriia SS; Kovaleva LG; Khoroshko ND
Ter Arkh; 2005; 77(7):42-7. PubMed ID: 16116908
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
34. Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.
Kreutzman A; Rohon P; Faber E; Indrak K; Juvonen V; Kairisto V; Voglová J; Sinisalo M; Flochová E; Vakkila J; Arstila P; Porkka K; Mustjoki S
PLoS One; 2011; 6(8):e23022. PubMed ID: 21857985
[TBL] [Abstract][Full Text] [Related]
35. Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells.
Cayssials E; Jacomet F; Piccirilli N; Lefèvre L; Roy L; Guilhot F; Chomel JC; Leleu X; Gombert JM; Herbelin A; Barbarin A
Br J Haematol; 2019 Jul; 186(1):54-59. PubMed ID: 30864168
[TBL] [Abstract][Full Text] [Related]
36. The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia.
Jiang Q; Zhao XY; Qin YZ; Liu YR; Lai YY; Jiang B; Huang XJ
Am J Hematol; 2012 Dec; 87(12):1065-9. PubMed ID: 22965919
[TBL] [Abstract][Full Text] [Related]
37. Aberrant T cell responses in the bone marrow microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
Kong Y; Wang YT; Cao XN; Song Y; Chen YH; Sun YQ; Wang Y; Zhang XH; Xu LP; Huang XJ
J Transl Med; 2017 Mar; 15(1):57. PubMed ID: 28292332
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in chronic myeloid leukemia].
Lai Y; Qin Y; Huang X; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):104-8. PubMed ID: 24606648
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Impact of Bone Marrow Fibrosis and Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid Leukemia.
Pepeler MS; Tıglıoglu M; Dagdas S; Ozhamamcıoglu E; Han U; Albayrak A; Aydın MS; Korkmaz G; Pamukcuoğlu M; Ceran F; Albayrak M; Ozet G
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e161-e167. PubMed ID: 38342726
[TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinase-9 was involved in the immuno-modulatory defect of mesenchymal stem cell from chronic myeloid leukemia patients.
Zhu XS; Shi W; An GY; Zhang HM; Song YG; Li YB
Chin Med J (Engl); 2011 Aug; 124(16):2423-30. PubMed ID: 21933581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
